Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Sep;18(3):383–392. doi: 10.1111/j.1365-2125.1984.tb02480.x

Disposition of betamethasone in parturient women after intramuscular administration.

M C Petersen, J J Ashley, W G McBride, R L Nation
PMCID: PMC1463657  PMID: 6487477

Abstract

When betamethasone phosphate equivalent to 8 mg betamethasone was administered intramuscularly in solution (Celestone Injection) to pregnant women, a large proportion of this ester was absorbed unchanged. Bioavailability of betamethasone from the phosphate ester was as high as after intravenous injection. When pregnant patients received the equivalent of either 6 or 12 mg betamethasone in a formulation containing 3.1 mg/ml betamethasone acetate suspended in a solution of 4 mg/ml betamethasone phosphate (Celestone Chronodose), much of the phosphate ester was absorbed intact but betamethasone acetate was not detected in plasma. Availability of betamethasone from Celestone Chronodose was much lower than from Celestone Injection. After administration of either formulation, maternal plasma cortisol concentrations fell towards a basal level but were rising again within 2 to 3 days of the last dose. We conclude that Celestone Chronodose does not provide prolonged release of betamethasone and offers no advantage over Celestone Injection.

Full text

PDF
383

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballard P. L., Ballard R. A. Corticosteroids and respiratory distress syndrome: status 1979. Pediatrics. 1979 Jan;63(1):163–165. [PubMed] [Google Scholar]
  2. Ballard P. L., Gluckman P. D., Liggins G. C., Kaplan S. L., Grumbach M. M. Steroid and growth hormone levels in premature infants after prenatal betamethasone therapy to prevent respiratory distress syndrome. Pediatr Res. 1980 Feb;14(2):122–127. doi: 10.1203/00006450-198002000-00011. [DOI] [PubMed] [Google Scholar]
  3. Ballard P. L., Granberg P., Ballard R. A. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. J Clin Invest. 1975 Dec;56(6):1548–1554. doi: 10.1172/JCI108236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ceresa F., Angeli A., Boccuzzi G., Perotti L. Impulsive and basal ACTH secretion phases in normal subjects, in obese subjects with signs of adrenocortical hyperfunction and in hyperthyroid patients. J Clin Endocrinol Metab. 1970 Nov;31(5):491–501. doi: 10.1210/jcem-31-5-491. [DOI] [PubMed] [Google Scholar]
  5. Gennser G., Ohrlander S., Eneroth P. Cortisol in amniotic fluid and cord blood in relation to prenatal betamethasone load and delivery. Am J Obstet Gynecol. 1976 Jan 1;124(1):43–50. doi: 10.1016/0002-9378(76)90009-0. [DOI] [PubMed] [Google Scholar]
  6. Liggins G. C., Howie R. N. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972 Oct;50(4):515–525. [PubMed] [Google Scholar]
  7. Maltau J. M., Stokke K. T., Moe N. Effects of betamethasone on plasma levels of estriol, cortisol and HCS in late pregnancy. Acta Obstet Gynecol Scand. 1979;58(3):235–238. doi: 10.3109/00016347909154040. [DOI] [PubMed] [Google Scholar]
  8. Ohrlander S. A., Gennser G. M., Grennert L. Impact of betamethasone load given to pregnant women on endocrine balance of fetoplacental unit. Am J Obstet Gynecol. 1975 Oct 1;123(3):228–236. doi: 10.1016/0002-9378(75)90190-8. [DOI] [PubMed] [Google Scholar]
  9. Ohrlander S., Gennser G., Nilsson K. O., Eneroth P. ACTH test to neonates after administration of corticosteroids during gestation. Obstet Gynecol. 1977 Jun;49(6):691–694. [PubMed] [Google Scholar]
  10. Petersen M. C., Collier C. B., Ashley J. J., McBride W. G., Nation R. L. Disposition of betamethasone in parturient women after intravenous administration. Eur J Clin Pharmacol. 1983;25(6):803–810. doi: 10.1007/BF00542524. [DOI] [PubMed] [Google Scholar]
  11. Petersen M. C., Nation R. L., Ashley J. J., McBride W. G. The placental transfer of betamethasone. Eur J Clin Pharmacol. 1980 Oct;18(3):245–247. doi: 10.1007/BF00563006. [DOI] [PubMed] [Google Scholar]
  12. Petersen M. C., Nation R. L., Ashley J. J. Simultaneous determination of betamethasone, betamethasone acetate and hydrocortisone in biological fluids using high-performance liquid chromatography. J Chromatogr. 1980 Aug 8;183(2):131–139. doi: 10.1016/s0378-4347(00)81686-2. [DOI] [PubMed] [Google Scholar]
  13. Petersen M. C., Nation R. L., McBride W. G., Ashley J. J., Moore R. G. Pharmacokinetics of betamethasone in healthy adults after intravenous administration. Eur J Clin Pharmacol. 1983;25(5):643–650. doi: 10.1007/BF00542353. [DOI] [PubMed] [Google Scholar]
  14. Sybulski S. Effect of antepartum betamethasone treatment on cortisol levels in cord plasma, amniotic fluid, and the neonate. Am J Obstet Gynecol. 1977 Apr 15;127(8):871–874. doi: 10.1016/0002-9378(77)90121-1. [DOI] [PubMed] [Google Scholar]
  15. Tsuei S. E., Petersen M. C., Ashley J. J., McBride W. G., Moore R. G. Disporition of synthetic glucocorticoids. II. Dexamethasone in parturient women. Clin Pharmacol Ther. 1980 Jul;28(1):88–98. doi: 10.1038/clpt.1980.136. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES